Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.36 |
| ▸ | CTSB | P07858 | 7/20 | 0.36 |
| ▸ | CTSK | P43235 | 7/20 | 0.36 |
| ▸ | CTSS | P25774 | 6/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419957 | 0.81 | MME (0.40) | CTSLCTSBCTSKCTSSPPARG | |
| SCHEMBL7548947 | 0.70 | NPC1 (0.45) | CTSLCTSBCTSKCTSSPPARG | |
| SCHEMBL26919628 | 0.69 | KMT2A (0.42) | METAP2PPARGPPARAACEL3MBTL1 | |
| SCHEMBL6589208 | 0.67 | CTSL (0.47) | CTSLCTSBCTSKCTSSPPARG | |
| SCHEMBL5428404 | 0.67 | METAP2 (0.56) | METAP2PPARGPPARAACEL3MBTL1 | |
| SCHEMBL3622043 | 0.67 | ACE (0.39) | CTSLCTSBCTSKCTSSPPARG | |
| SCHEMBL5422146 | 0.67 | CTSS (0.52) | CTSLCTSBCTSKCTSSACE | |
| SCHEMBL5418068 | 0.66 | CYP1A2 (0.55) | PPARGPPARAACE | |
| SCHEMBL20408297 | 0.65 | METAP2 (0.54) | METAP2PPARGPPARAACEL3MBTL1 | |
| SCHEMBL8500116 | 0.64 | PPARA (0.48) | METAP2PPARGPPARAACEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSL 11/4885CTSB 2/4885CTSK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.